$ACRX News

Last published 6mo ago

6mo agoACRX ANIK AXGN BEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
2y agoACRXAcelRx Announces Rebranding With Name Change to Talphera, Inc.PR NewswireAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
2y agoACRXAcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United StatesPR NewswireAcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...
3y agoACRXAcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoACRXAcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
3y agoACRXAcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical StudyPR NewswireAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
3y agoACRXAcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023PR NewswireAcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of...
3y agoACRXAcelRx Receives IDE Approval for Niyad and Advances to a Single Registration StudyPR NewswireInvestigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to
3y agoACRXAcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferencePR NewswireSAN MATEO, Calif., Sept. 6, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use
3y agoACRXAcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireCapital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx awaits response to Emergency Use Authorization (EUA) of
3y agoACRXAcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireTransformative capital raise, led by new investors including Nantahala Capital Management The private placement provides access to up to $26.3 million of gross proceeds upon the exercise of the milestone-affected
3y agoACRXAcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesPR NewswireUpon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full HAYWARD, Calif.,
3y agoACRXAcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireRequest for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 Webcast and
3y agoACRXAcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023PR NewswireHAYWARD, Calif., April 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically
3y agoACRXAcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora PharmaceuticalsPR NewswireIn connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif., April 5, 2023
3y agoACRXAcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireDivestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a strategic
3y agoACRXAcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023PR NewswireHAYWARD, Calif., March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically
3y agoACRXAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsPR NewswireAgreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone payments, and a
3y agoACRXAcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology ProceduresPR NewswireStudy is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historically conducted
3y agoACRXAcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common StockPR NewswireHAYWARD, Calif., Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in
3y agoACRXAcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical MedicinePR NewswirePatients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacement surgery adds to a
3y agoACRXAcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireInitial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M in the third quarter, a 217% increase over prior year $20.9 million in
4y agoACRXAcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022PR NewswireHAYWARD, Calif., Nov. 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market
4y agoACRXAcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022PR NewswireThe study of 324 complex plastic surgery procedures demonstrated many benefits of using DSUVIA for analgesia, including avoiding the need for general anesthesia HAYWARD, Calif., Oct. 31, 2022 /PRNewswire/ -- AcelRx
4y agoACRXAcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, AguettantPR NewswirePhysicians across Europe will now have access to DZUVEO®, a novel sublingual approach to acute pain management in medically supervised settings HAYWARD, Calif., Oct. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals,
4y agoACRXAcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022PR NewswireBrigham and Women's Hospital study found that SST-treated patients had significantly lower pain scores in the post-operative care unit (PACU) compared with patients in the two intravenous opioid control groups
4y agoACRXAcelRx Pharmaceuticals Announces Reverse Stock SplitPR NewswireHAYWARD, Calif., Oct. 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in
4y agoACRXAcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health SciencesPR NewswirePresentation concludes that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establish protocols for their implementation in the trauma setting HAYWARD,
4y agoACRXAcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment ConferencePR NewswireHAYWARD, Calif., Sept. 6, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t
4y agoACRXAcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual MeetingPR NewswireExperts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establish protocols for their implementation HAYWARD, Ca
4y agoACRXAcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireAdvanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth consecutive quarter of commercial (ex-DoD) sales volume growth for DSUVIA, with a 133% increase comp
4y agoACRXAcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022PR NewswireHAYWARD, Calif., Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, to
4y agoACRXAcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual MeetingPR NewswireHAYWARD, Calif., Aug. 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, tod
4y agoACRXAcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022PR NewswireHAYWARD, Calif., July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022. AcelRx
4y agoACRXAcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment ConferencePR NewswireHAYWARD, Calif., May 20, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, to
4y agoACRXAcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®PR NewswireHAYWARD, Calif., May 19, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t
4y agoACRXAcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePR NewswireRealigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million Completed acquisition of Lowell Therapeutics and nafamostat franchise, including Ni
4y agoACRXAcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General AnesthesiaPR NewswireStudy found that SST lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration HAYWARD, Calif., May 10, 2022 /PRNewswire/ -- AcelRx Pharmaceutical
4y agoACRXAcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022PR NewswireHAYWARD, Calif., May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before market open on Monday, May 16, 2022. AcelRx mana
4y agoACRXAcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat ProgramGlobeNewswireKey Opinion Leaders participating will be Stuart Goldstein, MD, Cincinnati Children's Hospital and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center Webinar to be hel
4y agoACRXMinimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022PR NewswireHAYWARD, Calif., April 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,
4y agoACRXAcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022PR NewswireHAYWARD, Calif., April 21, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,
4y agoACRXAcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling ProceduresPR NewswireStudy results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone HAYWARD, Calif., March 31, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACR
4y agoACRXAcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis CircuitPR NewswireStudy results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation. HAYWARD, Calif., March 29, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, In
4y agoACRXAcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsPR NewswireHAYWARD, Calif., March 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, t
4y agoACRXAcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022PR NewswireHAYWARD, Calif., March 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Thursday, March 10, 2022. AcelRx ma
4y agoACRXAcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery ProceduresPR NewswireHAYWARD, Calif., Feb. 1, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announce
4y agoACRXAcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine ProceduresPR NewswireHAYWARD, Calif., Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announc
4y agoACRXAcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement SurgeryPR NewswireHAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announc
4y agoACRXAcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell TherapeuticsPR NewswireHAYWARD, Calif., Jan. 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announc